Securing FDA approvals last year for three drugs that each have peak sales potential of $4 billion bodes well for the long-term future of Bristol Myers Squibb. | Bristol Myers Squibb is entering a dark stage. In the second quarter, the company’s three top-selling drugs—Eliquis, Revlimid and Opdivo—all meaningfully missed analysts’ expectations. And it’s projecting overall sales decline for 2023.
